New device aims to seal brain blood vessel leaks in kids
NCT ID NCT03731000
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the PHIL Embolic System works to treat a rare brain condition in children called dural arteriovenous fistulas (DAVFs), where blood vessels connect abnormally. About 15 children under 22 will receive the treatment, which uses a special material to block the faulty vessels. The goal is to see if it is safe and effective at stopping the abnormal blood flow.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2019
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject is \<22 years of age * Subject and legally authorized representative are willing and capable of complying with all study protocol requirements, including specified follow-up period. * Subject's legally authorized representative(s) must sign and date an IRB approved written informed consent prior to initiation of any study procedure * Subject has an intracranial dAVF that is deemed appropriate for embolization with PHIL without significantly increased risk to collateral or adjacent territories, OR subject has been previously treated with other embolic materials for dAVF. Exclusion Criteria: * Subject presents with an intracranial mass or is currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region * Subject has known allergies to DMSO (dimethyl sulfoxide), iodine or heparin. * Subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated). * Female subject is currently pregnant. * Subject has an acute or chronic life-threatening illness other than the neurological disease to be treated in this study including but not limited to any malignancy or debilitating autoimmune disease * Subject has existing severe or advanced comorbid conditions which significantly increase general anesthesia and/ or surgical risk * Evidence of active infection at the time of treatment. * Subject has a history of bleeding diathesis or coagulopathy, international normalized ratio (INR) greater than 1.5, or will refuse blood transfusions. * Subject weighs ≤ 2.5kg Angiographic * Subject has severe calcification or vascular tortuosity that may preclude the safe introduction of the sheath, guiding catheter, or access to the lesion with the microcatheter. * Contra-indication to DSA, CT scan or MRI/ MRA * History of intracranial vasospasm not responsive to medical therapy * Extra-cranial stenosis or parent vessel stenosis \> 50% proximal to the target lesion to be treated. * Subject has a propensity to contrast induced renal injury or a potential to nephrogenic systemic fibrosis
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arterio-venous fistula are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can fixing abnormal brain vessels help the brain clear its waste?
- Massive 15-year study launched to crack the code on rare brain-spine vessel disease
- New device aims to keep dialysis fistulas working longer
- Massive study explores safety of Office-Based blood vessel procedures
- Super-Strength balloon aims to keep dialysis lifelines open
- Tiny trial tests best way to create dialysis access